|
||||||||||||||||
HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
MOLECULAR DIVERSITY | ||||||||||||||||
December 05, 2000 | ||||||||||||||||
Cambridge Healthtech Institute, San Diego, California February 12-14, 2001 Combinatorial chemistry is now well established as a powerful tool for rapidly providing highly diverse compounds for hit discovery and for more focused lead optimization. Over the years, combichem researchers have become more realistic about the limitations of the technology, with experience teaching that improvements and enhancements are still required and possible. This conference will showcase a variety of topics including ways that library design and diversity assessment can be used to better match a library to biological targets, as well as more efficient means of design, synthesis, testing, and analysis. In addition, the experiences and research of end-users and those involved with the production of compounds entering clinical trials will be presented. Plan now to participate in this meeting, which offers you a time-efficient means of keeping up with the latest developments and understanding as presented by your experienced colleagues. |
||||||||||||||||
Organized by: | Cambridge Healthtech Institute | |||||||||||||||
Invited Speakers: | Dr. D. Benjamin Borson, Fleister, Dubb, Meyer & Lovejoy, LLP Dr. Valery Alakhov, Supratek Pharma, Inc. Dr. Nigel R.A. Beeley, Arena Pharmaceuticals Inc. Dr. D. Dunn, Pharmacopeia, Inc. Dr. Adam Golebiowski, Procter & Gamble Pharmaceuticals Dr. Burt Goodman, Molecumetics Dr. Erich L. Grimm, Merck Frosst Centre for Therapeutic Research Dr. Thomas F. Hendrickson, Agouron Pharmaceuticals, Inc. Dr. Richard A. Houghten, Torrey Pines Institute for Molecular Studies Dr. Duncan B. Judd, GlaxoWellcome Medicines Research Centre UK Dr. Kevin Koch, Array BioPharma Mr. Paul Labute, Chemical Computing Group Inc. Dr. Roger Lahana, Synt:em, Inc. Dr. Christian Lemmen, DuPont Pharmaceuticals Research Labs Dr. Victor S. Lobanov, 3-Dimensional Pharmaceuticals, Inc. Dr. David R. Lowis, Tripos, Inc. Dr. Chester A. Metcalf III, ARIAD Pharmaceuticals, Inc. Dr. Adnan Mjalli, TransTech Pharma, Inc. Dr. Isabelle Morize, Aventis Pharmaceuticals Dr. Dora M. Schnur, Bristol-Myers Squibb Company Dr. Daniel Sem, Triad Therapeutics, Inc. Dr. Duane L. Venton, University of Illinois at Chicago Dr. Dirk Vetter, Graffinity Pharmaceuticals Design Gmbh Dr. Edward A. Wintner, NeoGenesis, Inc. Dr. Liqun Yang, Glaxo Wellcome R&D |
|||||||||||||||
Deadline for Abstracts: | January 5, 2001 | |||||||||||||||
Registration: | Available on-line | |||||||||||||||
E-mail: | jlaakso@healthtech.com | |||||||||||||||
Posted by: | Jennifer Laakso | |||||||||||||||
Host: | wks217.healthtech.com | |||||||||||||||
|
||||||||||||||||
Generated by meetings and positions 5.0 by Kai Garlipp |